Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches
about
MiRNA expression patterns predict survival in glioblastomaMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsRadiotherapy and "new" drugs-new side effects?Resistance and escape from antiangiogenesis therapy: clinical implications and future strategiesLow incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stagesAnalysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma.Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort.IDH1-associated primary glioblastoma in young adults displays differential patterns of tumour and vascular morphologyRecurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patientsCilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.Novel therapies in glioblastoma.The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled TrialsMechanisms of glioma-associated neovascularization.Standards of care for treatment of recurrent glioblastoma--are we there yet?Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.Efficacy and safety of bevacizumab for the treatment of glioblastoma.Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudyPhase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observationsTime trends in glioblastoma multiforme survival: the role of temozolomide.A 4-miRNA signature predicts the therapeutic outcome of glioblastoma.Current concepts in clinical radiation oncology.Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation.Angiogenesis in neurological disorders: a review.Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigensBevacizumab in recurrent glioblastoma: five informative patient scenarios.Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism.Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.Angiogenesis inhibitors in tackling recurrent glioblastoma.CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapyELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.Intensity-modulated fractionated stereotactic radiotherapy with reduced margin for high grade gliomas: dosimetric analysis of sparing optic nerve & chiasm.Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
P2860
Q24629525-D660277F-D4EF-4D1B-B1F5-19338B0E8A49Q26853516-6076C464-3B8F-49AA-8D80-B732B421BA59Q26861498-EDEC44EE-3CBE-43F1-9ECA-4FD1C9D4E0ACQ27016629-C92A64BE-D93E-4AD1-BC29-2527FE6B85F0Q30708866-AFB35DDD-4EDD-4815-B00E-4AB891BF3FFEQ33618760-C0DA1E6D-9E91-4C67-80F7-9BF49E6F2283Q33642508-54930B74-6D45-4B89-808C-1D5DDF4072E0Q33851320-A6BD0E30-3F19-4604-A443-13448A09745AQ34602320-B5D468D7-9467-487B-B4E9-23DC95C805E1Q35018538-0B973374-95AF-4654-ACB3-274E2E43F96AQ35078406-5AE6A7D4-6777-420B-B6C1-8C170B8D26D0Q35692849-3A828919-48E0-4DAF-9DC7-841E65925838Q35864136-31A53B03-2A84-4F09-98FC-69368E504705Q36231572-9547627C-E8D0-4509-B985-9ED22F6AD1BAQ36295477-E325FD1A-9226-4BB9-8090-C17ADBCCDBD3Q36500401-5975AE01-6FDF-46E5-A8E3-0BD32F8749E2Q36511945-E532A9D1-D0EB-498A-9C74-A6C19F2E166BQ36523864-C956A62B-EBB8-45F5-814E-27414E4177B2Q36544494-91C67659-5978-412D-8FAB-E89F20BD70C8Q36627197-571A93F6-3886-4938-ABF4-33E54417D9E7Q36893213-A27BD998-332B-465E-9A4C-5D89FBA25C0BQ36943907-AED5B720-61F3-4A2D-934A-159D85DA6054Q37187676-56E81FEB-712A-4C33-9C29-1EBB41F2FD58Q37255838-AD85DF9D-2668-4242-9B8A-22A4E85B0731Q37312701-C9F79DDE-9D1B-4A63-871F-E2C211C5E853Q37564551-86EEC5B9-1324-458C-8173-25AB48B87ACBQ37603804-A0680988-257F-491E-B4AE-218563ECE485Q37973261-23A4AE85-1246-4E24-8F59-DF41AD96F474Q38034321-013BB7A4-355E-4DAC-B44A-866B6D098A36Q38241483-C8E6C5ED-3D78-4214-B3C5-3DD899647973Q38409696-D9F789C9-3364-471A-8099-83048294A6EDQ38635290-A289FB81-4B5B-451F-A0F4-4E084E4DF090Q38724990-F38E4C6A-996E-4A6A-BE16-053DEF4D405AQ38989530-D1114F04-293D-4943-97CE-9163448E3D95Q39259089-04990293-37A6-4430-83DD-D16C5C72BB85Q39300421-1F035DFC-3EDD-46F8-910D-77A3CF864129Q39601750-E2CED65F-9338-415B-9937-D2A2F966B127Q42143173-DD205040-7E25-4F5B-AFDD-31ECBA315740Q47157031-8B01BDFC-1764-4EFA-9545-46B255A8CA79Q51754497-D08C8D69-1BF1-4FD4-B653-9E102C580F70
P2860
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antiangiogenic agents in the t ...... d combined modality approaches
@ast
Antiangiogenic agents in the t ...... d combined modality approaches
@en
Antiangiogenic agents in the t ...... d combined modality approaches
@nl
type
label
Antiangiogenic agents in the t ...... d combined modality approaches
@ast
Antiangiogenic agents in the t ...... d combined modality approaches
@en
Antiangiogenic agents in the t ...... d combined modality approaches
@nl
prefLabel
Antiangiogenic agents in the t ...... d combined modality approaches
@ast
Antiangiogenic agents in the t ...... d combined modality approaches
@en
Antiangiogenic agents in the t ...... d combined modality approaches
@nl
P2093
P2860
P921
P356
P1433
P1476
Antiangiogenic agents in the t ...... d combined modality approaches
@en
P2093
Kathryn Beal
Lauren E Abrey
Philip H Gutin
P2860
P2888
P356
10.1186/1748-717X-6-2
P5008
P577
2011-01-07T00:00:00Z
P6179
1053158223